Roche Holding AG (RHHBY.PK) Tuesday said its received clearance from the US Food and Drug Administration for its IgG Antibody to herpes simplex virus types 1 and 2 assays for use on cobas modular platforms.
The tests are intended for use with sexually active individuals and expectant mothers as an aid in the presumptive diagnosis of HSV-1 and HSV-2 infection.
"These are the first automated type-specific herpes tests available for integrated analyzer platforms, which will enable labs to integrate efficient herpes testing into their existing workflow," said Randy Pritchard, vice president of marketing at Roche Diagnostics Corporation.
Herpes Simplex Virus Type 1 is transmitted through social contacts during childhood, while Type 2 is usually transmitted sexually.
Click here to receive FREE breaking news email alerts for Roche Holding AG and others in your portfolio
by RTT Staff Writer
For comments and feedback: editorial@rttnews.com
Business News